Role of Haloperidol in Palliative Medicine: An Update

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 4, 2012, Pages 295-301

  Prommer, Eric ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

delirium; dopamine; dosing; haloperidol; nausea; QT interval

Indexed keywords

EID: 84865497434     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111423094     Document Type: Review

References (51)

1. Cecilio LM.The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.Brain Res Bull. 2009;79 (2): 130-141.
2. Reed LL,Schaefer JP.The crystal and molecular structure of haloperidol, a potent psychotropic drug.Acta Crystallogr Sect B. 1973;29 (9): 1886-1890.
3. Ablordeppey S,Glennon RSigma Receptors. 2007:71-98.
4. Stahl SM,Shayegan DK.The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.J Clin Psychiatry. 2003;64 (suppl 19): 6-12.
5. Schotte A,Janssen PFM,Gommeren W, et al.Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology. 1996;124 (1): 57-73.
6. Dickman A,Schneider J,Varga JThe Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care. New york, NY: Oxford University Press; 2005:.
7. Kudo S,Ishizaki T.Pharmacokinetics of haloperidol: an update.Clin Pharmacokinet. 1999;37 (6): 435-456.
8. Holley FO,Magliozzi JR,Stanski DR,Lombrozo L,Hollister LE.Haloperidol kinetics after oral and intravenous doses.Clin Pharmacol Ther. 1983;33 (4): 477-484.
9. Schaffer CB,Shahid A,Javaid JI,Dysken MW,Davis JM.Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.J Clin Psychopharmacol. 1982;2 (4): 274.
10. Bleicher J,Bhaskara A,Huyck T, et al.Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.J Support Oncol. 2008;6 (1): 27.
11. Gupta SK,Southam M,Hwang S.Pharmacokinetics of droperidol in healthy volunteers following intravenous infusion and rectal administration from an osmotic drug delivery module.Pharm Res. 1992;9 (5): 694-696.
12. Forsman A,Öhman R.On the pharmacokinetics of haloperidol.Nord J Psychiatr. 1974;28 (6): 441-448.
13. Fang J,Baker GB,Silverstone PH,Coutts RT.Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.Cell Mol Neurobiol. 1997;17 (2): 227-233.
14. Oida T,Terauchi Y,Yoshida K,Kagemoto A,Sekine Y.Use of antisera in the isolation of human specific conjugates of haloperidol.Xenobiotica. 1989;19 (7): 781-793.
15. Someya T,Shibasaki M,Noguchi T,Takahashi S,INABA T.Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.J Clin Psychopharmacol. 1992;12 (3): 169-174.
16. Subramanyam B,Pond SM,Eyles DW,Whiteford HA,Fouda HG,Castagnoli N.Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.Biochem Biophys Res Commun. 1991;181 (2): 573-578.
17. Gupta SK,Kunka RL,Metz A,Lloyd T,Rudolph G,Perel JM.Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.J Clin Pharmacol. 1995;35 (2): 202-207.
18. Blaschke TF.Protein binding and kinetics of drugs in liver diseases.Clin Pharmacokinet. 1997;2 (1): 32-44.
19. Jann MW,Ereshefsky L,Saklad SR, et al.Effects of carbamazepine on plasma haloperidol levels.J Clin Psychopharmacol. 1985;5 (2): 106-109.
20. Linnoila M,Viukari M,Vaisanen K,Auvinen J.Effect of anticonvulsants on plasma haloperidol and thioridazine levels.Am J Psychiatry. 1980;137 (7): 819-821.
21. Daniel DG,Randolph C,Jaskiw G, et al.Coadministration of fluvoxamine increases serum: concentrations of haloperidol.J Clin Psychopharmacol. 1994;14 (5): 340-343.
22. Barbhaiya RH,Shukla UA,Greene DS,Breuel HP,Midha KK.Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.J Clin Psychopharmacol. 1996;16 (1): 26-34.
23. 52 ed. Montvale, NJ: Medical Economics Company; 1998:3037-3041.Montvale, NJ: Medical Economics Company; 1998:3037-3041.
24. Lee MS,Kim YK,Lee SK,Suh KY.A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.J Clin Psychopharmacol. 1998;18 (5): 399-403.
25. Syv-Lahti E,Taiminen T,SaarijSrvi S, et al.Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients.J Int Med Res. 1997;25 (1): 24-32.
26. Stevens A,Stevens I,Mahal A,Gaertner HJ.Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.Pharmacopsychiatry. 1992;25:273-277.
27. Breitbart W,Marotta R,Platt MM, et al.A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.Focus. 2005;3 (2): 333.
28. Hedges D,Jeppson K,Whitehead P.Antipsychotic medication and seizures: a review.Drugs Today. 2003;39 (7): 551-557.
29. Remick RA,Fine SH.Antipsychotic drugs and seizures.J Clin Psychiatry. 1979;40 (2): 78.
30. Pisani F,Oteri G,Costa C,Di Raimondo G,Di Perri R.Effects of psychotropic drugs on seizure threshold.Drug Saf. 2002;25 (2): 91-110.
31. BenzerT. Neuroleptic malignant syndrome. 2002;19:2004. http://www.emedicine.com/EMERG/topic339.html.
32. Bellamy CJ,Kane-Gill SL,Falcione BA,Seybert AL.Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol.J Trauma. 2009;66 (3): 954-958.
33. Jackson N,Doherty J,Coulter S.Neuropsychiatric complications of commonly used palliative care drugs.Postgrad Med. 2008;84 (989): 121-126.
34. Rosenberg MR,Green M.Neuroleptic malignant syndrome: review of response to therapy.Arch Intern Med. 1989;149 (9): 1927-1931.
35. Han CS,Kim YK.A double-blind trial of risperidone and haloperidol for the treatment of delirium.Psychosomatics. 2004;45 (4): 297-301.
36. Skrobik YK,Bergeron N,Dumont M,Gottfried SB.Olanzapine vs haloperidol: treating delirium in a critical care setting.Intensive Care Med. 2004;30 (3): 444-449.
37. Critchley P,Plach N,Grantham M, et al.Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review.J Pain Symptom Manage. 2001;22 (2): 631.
38. Lichter I.Results of antiemetic management in terminal illness.J Palliat Care. 1993;9 (2): 19-21.
39. Ventafridda V,Ripamonti C,Caraceni A,Spoldi E,Messina L,De Conno F.The management of inoperable gastrointestinal obstruction in terminal cancer patients.Tumori. 1990;76 (4): 389-393.
40. Kumar A,Dromerick AW.Intractable hiccups during stroke rehabilitation.Arch Phys Med Rehabil. 1998;79 (6): 697-699.
41. Ives TJ,Fleming MF,Weart CW,Bloch D.Treatment of intractable hiccups with intramuscular haloperidol.Am J Psychiatry. 1985;142 (11): 1368-1368.
42. Chiu TY,Hu WY,Lue BH,Cheng SY,Chen CY.Sedation for refractory symptoms of terminal cancer patients in Taiwan.J Pain Symptom Manage. 2001;21 (6): 467-472.
43. Vella-Brincat J,Macleod AD.Haloperidol in palliative care.Palliat Med. 2004;18 (3): 195-201.
44. Hui D,Bush SH,Gallo LE,Palmer JL,Yennurajalingam S,Bruera E.Neuroleptic dose in the management of delirium in patients with advanced cancer.J Pain Symptom Manage. 2010;39 (2): 186-196.
45. Breitbart W,Cohen K.Delirium in the Terminally.Handb Psychiatry Palliat Med. 2000;:75.
46. Canadian Coalition for Seniors' Mental Health, National guidelines for seniors' mental health: the assessment and treatment of delirium. Canadian Coalition for Seniors' Mental Health, National guidelines 2010. http://www.ccsmh.ca/en/guidelinesusers.cfm. Accessed November 3, 2008.
47. Lipowski ZJDelirium: Acute Confusional States. New York, NY: Oxford University Press; 1990:2010.
48. Akechi T,Uchitomi Y,Okamura H, et al.Usage of haloperidol for delirium in cancer patients.Support Care Cancer. 1996;4 (5): 390-392.
49. Storey P,Hill HH.Subcutaneous infusions for control of cancer symptoms.J Pain Symptom Manage. 1990;5 (1): 33-41.
50. Ripamonti C,Twycross R,Baines M, et al.Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer.Support Care Cancer. 2001;9 (4): 223-233.
51. Rousseau P.Palliative sedation in the management of refractory symptoms.J Support Oncol. 2 (2): 181.